RESUMEN
OBJECTIVES: To study the diagnosis, treatment, and complications of hypophosphatemic rickets (HR) in children, explore effectiveness evaluation indicators for the disease, and understand the pattern in height growth among these patients. METHODS: A retrospective analysis of the initial clinical data and five-year follow-up data of 85 children with HR treated at Children's Hospital of Nanjing Medical University from January 2008 to December 2022. RESULTS: Among the 85 children with HR, there were 46 males (54%) and 39 females (46%). The age at initial diagnosis ranged from 6 months to 13 years and 9 months, with a median age of 2.75 years. The average height standard deviation score was -2.0±1.1. At initial diagnosis, children exhibited reduced blood phosphate levels and elevated alkaline phosphatase (ALP), with 99% (84/85) presenting with lower limb deformities. The positive rate for PHEX gene mutations was 93% (55/59). One year post-treatment, there was a significant reduction in ALP levels and the gap between the lower limbs (P<0.05). The fastest height growth occurred in the first year after treatment, at 8.23 cm/year, with a peak height velocity (PHV) phase lasting about two years during puberty. The height increased by 9-20 cm in male children during the PHV stage and 10-15 cm in female children. Major complications included nephrocalcinosis and hyperparathyroidism. The incidence rate of nephrocalcinosis in the first year after treatment was 55% (22/40), which increased with the duration of the disease (P<0.001); an increased urinary phosphate/creatinine ratio was positively associated with a higher risk of nephrocalcinosis (OR=1.740, P<0.001). The incidence of hyperparathyroidism in the first year after treatment was 64% (27/42). CONCLUSIONS: For children presenting with lower limb deformities, short stature, and slow growth, early testing for blood levels of phosphate, calcium, and ALP, along with imaging examinations of the lower limbs, can aid in the early diagnosis of HR. Genetic testing may be utilized for definitive confirmation when necessary. ALP combined with improvements in skeletal deformities and annual height growth can serve as indicators of therapeutic effectiveness for HR. Compared to normal children, children with HR demonstrate a lower height increase during the PHV phase, necessitating close follow-up and timely adjustment of treatment plans Citation:Chinese Journal of Contemporary Pediatrics, 2024, 26(7): 677-682.
Asunto(s)
Raquitismo Hipofosfatémico , Humanos , Masculino , Femenino , Niño , Estudios Retrospectivos , Preescolar , Lactante , Adolescente , Estudios de Seguimiento , Raquitismo Hipofosfatémico/genética , Raquitismo Hipofosfatémico/etiología , Fosfatasa Alcalina/sangre , Estatura , Endopeptidasa Neutra Reguladora de Fosfato PHEX/genética , Fosfatos/sangre , MutaciónRESUMEN
Hypophosphatemic rickets typically presents in infancy or early childhood with skeletal deformities and growth plate abnormalities. The most common causes are genetic (such as X-linked hypophosphatemia), and these typically will result in lifelong hypophosphatemia and osteomalacia. Knowledge of phosphate metabolism, including the effects of fibroblast growth factor 23 (FGF23) (an osteocyte produced hormone that downregulates renal phosphate reabsorption and 1,25-dihydroxyvitamin-D (1,25(OH)2D) production), is critical to determining the underlying genetic or acquired causes of hypophosphatemia and to facilitate appropriate treatment. Serum phosphorus should be measured in any child or adult with musculoskeletal complaints suggesting rickets or osteomalacia. Clinical evaluation incudes thorough history, physical examination, laboratory investigations, genetic analysis (especially in the absence of a guiding family history), and imaging to establish etiology and to monitor severity and treatment course. The treatment depends on the underlying cause, but often includes active forms of vitamin D combined with phosphate salts, or anti-FGF23 antibody treatment (burosumab) for X-linked hypophosphatemia. The purpose of this article is to explore the approach to evaluating hypophosphatemic rickets and its treatment options.
Asunto(s)
Raquitismo Hipofosfatémico Familiar , Hipofosfatemia , Osteomalacia , Raquitismo Hipofosfatémico , Adulto , Niño , Preescolar , Humanos , Raquitismo Hipofosfatémico Familiar/diagnóstico , Raquitismo Hipofosfatémico Familiar/tratamiento farmacológico , Raquitismo Hipofosfatémico Familiar/genética , Osteomalacia/metabolismo , Factores de Crecimiento de Fibroblastos/metabolismo , Raquitismo Hipofosfatémico/etiología , Raquitismo Hipofosfatémico/genética , FosfatosRESUMEN
Inorganic phosphate (Pi) in the mammalian body is balanced by its influx and efflux through the intestines, kidneys, bones, and soft tissues, at which several sodium/Pi co-transporters mediate its active transport. Pi homeostasis is achieved through the complex counter-regulatory feedback balance between fibroblast growth factor 23 (FGF23), 1,25-dihydroxyvitamin D (1,25(OH)2D), and parathyroid hormone. FGF23, which is mainly produced by osteocytes in bone, plays a central role in Pi homeostasis and exerts its effects by binding to the FGF receptor (FGFR) and αKlotho in distant target organs. In the kidneys, the main target, FGF23 promotes the excretion of Pi and suppresses the production of 1,25(OH)2D. Deficient and excess FGF23 result in hyperphosphatemia and hypophosphatemia, respectively. FGF23-related hypophosphatemic rickets/osteomalacia include tumor-induced osteomalacia and various genetic diseases, such as X-linked hypophosphatemic rickets. Coverage by the national health insurance system in Japan for the measurement of FGF23 and the approval of burosumab, an FGF23-neutralizing antibody, have had a significant impact on the diagnosis and treatment of FGF23-related hypophosphatemic rickets/osteomalacia. Some of the molecules responsible for genetic hypophosphatemic rickets/osteomalacia are highly expressed in osteocytes and function as local regulators of FGF23 production. A number of systemic factors also regulate FGF23 levels. Although the mechanisms responsible for Pi sensing in mammals have not yet been elucidated in detail, recent studies have suggested the involvement of FGFR1. The further clarification of the mechanisms by which osteocytes detect Pi levels and regulate FGF23 production will lead to the development of better strategies to treat hyperphosphatemic and hypophosphatemic conditions.
Asunto(s)
Raquitismo Hipofosfatémico Familiar , Hipofosfatemia , Osteomalacia , Fosfatos , Raquitismo Hipofosfatémico , Animales , Raquitismo Hipofosfatémico Familiar/etiología , Raquitismo Hipofosfatémico Familiar/metabolismo , Factores de Crecimiento de Fibroblastos , Homeostasis , Humanos , Hipofosfatemia/etiología , Hipofosfatemia/metabolismo , Mamíferos , Osteomalacia/etiología , Osteomalacia/metabolismo , Fosfatos/metabolismo , Raquitismo Hipofosfatémico/etiología , Raquitismo Hipofosfatémico/metabolismoRESUMEN
Here, we discuss the management of different forms of rickets, including new therapeutic approaches based on recent guidelines. Management includes close monitoring of growth, the degree of leg bowing, bone pain, serum phosphate, calcium, alkaline phosphatase as a surrogate marker of osteoblast activity and thus degree of rickets, parathyroid hormone, 25-hydroxyvitamin D3, and calciuria. An adequate calcium intake and normal 25-hydroxyvitamin D3 levels should be assured in all patients. Children with calcipenic rickets require the supplementation or pharmacological treatment with native or active vitamin D depending on the underlying pathophysiology. Treatment of phosphopenic rickets depends on the underlying pathophysiology. Fibroblast-growth factor 23 (FGF23)-associated hypophosphatemic rickets was historically treated with frequent doses of oral phosphate salts in combination with active vitamin D, whereas tumor-induced osteomalacia (TIO) should primarily undergo tumor resection, if possible. Burosumab, a fully humanized FGF23-antibody, was recently approved for treatment of X-linked hypophosphatemia (XLH) and TIO and shown to be superior for treatment of XLH compared to conventional treatment. Forms of hypophosphatemic rickets independent of FGF23 due to genetic defects of renal tubular phosphate reabsorption are treated with oral phosphate only, since they are associated with excessive 1,25-dihydroxyvitamin D production. Finally, forms of hypophosphatemic rickets caused by Fanconi syndrome, such as nephropathic cystinosis and Dent disease require disease-specific treatment in addition to phosphate supplements and active vitamin D. Adjustment of medication should be done with consideration of treatment-associated side effects, including diarrhea, gastrointestinal discomfort, hypercalciuria, secondary hyperparathyroidism, and development of nephrocalcinosis or nephrolithiasis.
Asunto(s)
Raquitismo Hipofosfatémico Familiar , Síndrome de Fanconi , Raquitismo Hipofosfatémico , Raquitismo , Calcio/uso terapéutico , Niño , Raquitismo Hipofosfatémico Familiar/tratamiento farmacológico , Raquitismo Hipofosfatémico Familiar/genética , Factores de Crecimiento de Fibroblastos , Humanos , Osteomalacia , Síndromes Paraneoplásicos , Fosfatos , Raquitismo/tratamiento farmacológico , Raquitismo/etiología , Raquitismo Hipofosfatémico/tratamiento farmacológico , Raquitismo Hipofosfatémico/etiología , Vitamina D/uso terapéuticoRESUMEN
BACKGROUND: Hypophosphatasia (HPP) is a rare metabolic bone disorder caused by mutations in the alkaline phosphatase (ALPL) gene, and characterized by low circulating alkaline phosphatase (ALP) levels and bone, muscle, dental and systemic manifestations. In this case series we investigate the clinical spectrum, genetic and biochemical profile of adult HPP patients from the University Hospitals Leuven, Belgium. METHODOLOGY: Adults with HPP were identified through medical record review. Inclusion criteria were: (1) age ≥ 16 yr; (2) consecutively low ALP levels not explained by secondary causes; (3) one or more of the following supporting criteria: biochemical evidence of elevated enzyme substrates; subtrochanteric fractures, metatarsal fractures or other typical clinical features; family history of HPP; a known or likely pathogenic ALPL mutation. RESULTS: Nineteen patients met our inclusion criteria (nâ¯=â¯2 infantile, nâ¯=â¯6 childhood, nâ¯=â¯10 adult-onset HPP and one asymptomatic carrier). Fractures and dental abnormalities were the most reported symptoms. Fatigue was reported in nâ¯=â¯7/19 patients (37%), three of which had previously been misdiagnosed as having chronic fatigue syndrome and/or fibromyalgia. Empirical pyridoxine therapy in four patients (without seizures) did not provide symptomatic relief. Nâ¯=â¯7/19 patients (37%) were inappropriately treated or planned to be treated with antiresorptive treatment. Two patients developed atypical femoral fractures following exposure to bisphosphonates and/or denosumab. Patients detected by screening were less severely affected, while patients with homozygous or compound heterozygous mutations had the most severe symptoms, significantly lower circulating ALP levels (pâ¯=â¯0.013) and significantly higher pyridoxal-5'-phosphate (pâ¯=â¯0.0018) and urinary phosphoethanolamine (pâ¯=â¯0.0001) concentrations. CONCLUSIONS: Screening may detect mainly less severely affected individuals, which may nevertheless avoid misdiagnosis and inappropriate antiresorptive drug exposure. Patients with biallelic mutations had more severe symptoms, significantly lower ALP and higher substrate levels. Whether the latter finding has implications for the classification and treatment of HPP should be investigated further in larger cohorts.
Asunto(s)
Fosfatasa Alcalina/genética , Etanolaminas/orina , Fracturas Óseas/fisiopatología , Hipofosfatasia/metabolismo , Fosfato de Piridoxal/sangre , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Fosfatasa Alcalina/metabolismo , Conservadores de la Densidad Ósea/efectos adversos , Denosumab/efectos adversos , Difosfonatos/efectos adversos , Epilepsia/tratamiento farmacológico , Epilepsia/etiología , Epilepsia/fisiopatología , Fatiga/etiología , Fatiga/fisiopatología , Femenino , Fracturas del Fémur/inducido químicamente , Fracturas del Fémur/etiología , Fracturas del Fémur/fisiopatología , Fracturas no Consolidadas/etiología , Fracturas no Consolidadas/fisiopatología , Trastornos del Crecimiento/etiología , Trastornos del Crecimiento/fisiopatología , Fracturas de Cadera/etiología , Fracturas de Cadera/fisiopatología , Humanos , Hipofosfatasia/complicaciones , Hipofosfatasia/genética , Hipofosfatasia/fisiopatología , Cálculos Renales/etiología , Cálculos Renales/fisiopatología , Masculino , Huesos Metatarsianos/lesiones , Persona de Mediana Edad , Piridoxina/uso terapéutico , Raquitismo Hipofosfatémico/etiología , Raquitismo Hipofosfatémico/fisiopatología , Índice de Severidad de la Enfermedad , Pérdida de Diente/etiología , Pérdida de Diente/fisiopatología , Complejo Vitamínico B/uso terapéutico , Adulto JovenRESUMEN
Tumor-induced osteomalacia is a rare hypophosphatemic disease caused by unregulated production of fibroblast growth factor 23 by a tumor, thereby inducing renal phosphate wasting and inhibiting appropriate increase of calcitriol production. Symptoms of tumor-induced osteomalacia, including muscle weakness, bone pain, and pathologic fractures, are nonspecific and warrant further workup. We report the case of a 50-year-old African American female with no known psychiatric illness who was admitted after a failed suicide attempt provoked by severe bone pain. She had been treated for fibromyalgia and hypophosphatemic rickets at other facilities with no improvement. The findings of profound renal phosphate wasting initiated further evaluation, which revealed an elevated fibroblast growth factor 23 level and a right proximal fibular mesenchymal tumor on octreotide scintigraphy. Magnetic resonance imaging confirmed the findings of a solid intramuscular tumor corresponding to the octreotide avid lesion. After wide excision of the tumor, serum phosphate and parathyroid hormone levels began to normalize. This case highlights the importance of extensively investigating the cause of bone pain, weakness, and fatigue in patients without a family history of hypophosphatemia or bone disorders. The aforementioned symptoms may precede recurrent pathological fractures, and a thorough workup ensures that a diagnosis of tumor is not delayed or overlooked, as tumor resection confers a favorable prognosis and dramatic increase in the quality of life for patients.
Asunto(s)
Factores de Crecimiento de Fibroblastos/sangre , Neoplasias de Tejido Conjuntivo/diagnóstico , Síndromes Paraneoplásicos/diagnóstico , Intento de Suicidio/psicología , Diagnóstico Tardío/psicología , Femenino , Factor-23 de Crecimiento de Fibroblastos , Fibromialgia/etiología , Humanos , Hipofosfatemia/etiología , Imagen por Resonancia Magnética , Persona de Mediana Edad , Neoplasias de Tejido Conjuntivo/sangre , Neoplasias de Tejido Conjuntivo/complicaciones , Osteomalacia , Dolor/etiología , Síndromes Paraneoplásicos/sangre , Síndromes Paraneoplásicos/complicaciones , Fosfatos/sangre , Cintigrafía , Raquitismo Hipofosfatémico/etiologíaRESUMEN
Elemental formula is commonly used in children with feeding intolerance. We describe two, medically complex and feeding tube dependent, patients exclusively fed with Neocate® who subsequently developed hypophosphatemic rickets. Both patients had gross motor decline and pain with physical touch. They were found to have low serum phosphorus, normal calcium, and vitamin D studies, with elevated alkaline phosphatase suggestive of nutritional hypophosphatemia. Both courses were complicated by hypocalcemia following formula change and phosphorus supplementation, highlighting the need for careful management of phosphate repletion in affected individuals. Diligent serial electrolyte monitoring as well as attention to bone health is needed in conjunction with elemental nutrition. Formula change led to restoration of calcium and phosphorus homeostasis and radiographic improvement in these patients.
Asunto(s)
Aminoácidos/efectos adversos , Carbohidratos/efectos adversos , Grasas de la Dieta/efectos adversos , Alimentos Formulados/efectos adversos , Raquitismo Hipofosfatémico/etiología , Preescolar , Humanos , Masculino , Radiografía , Raquitismo Hipofosfatémico/diagnóstico por imagenAsunto(s)
Aminoácidos/efectos adversos , Carbohidratos/efectos adversos , Grasas de la Dieta/efectos adversos , Fórmulas Infantiles/efectos adversos , Fosfatos/administración & dosificación , Raquitismo Hipofosfatémico/etiología , Ataxia/diagnóstico , Ataxia/etiología , Australia , Servicio de Urgencia en Hospital , Estudios de Seguimiento , Humanos , Lactante , Masculino , Fosfatos/metabolismo , Insuficiencia Respiratoria/diagnóstico , Insuficiencia Respiratoria/etiología , Raquitismo Hipofosfatémico/fisiopatología , Raquitismo Hipofosfatémico/terapia , Medición de Riesgo , Resultado del TratamientoRESUMEN
Tight control of extracellular and intracellular inorganic phosphate (Pi) levels is critical to most biochemical and physiologic processes. Urinary Pi is freely filtered at the kidney glomerulus and is reabsorbed in the renal tubule by the action of the apical sodium-dependent phosphate transporters, NaPi-IIa/NaPi-IIc/Pit2. However, the molecular identity of the protein(s) participating in the basolateral Pi efflux remains unknown. Evidence has suggested that xenotropic and polytropic retroviral receptor 1 (XPR1) might be involved in this process. Here, we show that conditional inactivation of Xpr1 in the renal tubule in mice resulted in impaired renal Pi reabsorption. Analysis of Pi transport in primary cultures of proximal tubular cells or in freshly isolated renal tubules revealed that this Xpr1 deficiency significantly affected Pi efflux. Further, mice with conditional inactivation of Xpr1 in the renal tubule exhibited generalized proximal tubular dysfunction indicative of Fanconi syndrome, characterized by glycosuria, aminoaciduria, calciuria, and albuminuria. Dramatic alterations in the renal transcriptome, including a significant reduction in NaPi-IIa/NaPi-IIc expression, accompanied these functional changes. Additionally, Xpr1-deficient mice developed hypophosphatemic rickets secondary to renal dysfunction. These results identify XPR1 as a major regulator of Pi homeostasis and as a potential therapeutic target in bone and kidney disorders.
Asunto(s)
Síndrome de Fanconi/etiología , Nefronas , Receptores Acoplados a Proteínas G/fisiología , Receptores Virales/fisiología , Raquitismo Hipofosfatémico/etiología , Animales , Femenino , Masculino , Ratones , Receptor de Retrovirus Xenotrópico y PolitrópicoRESUMEN
Through the studies of patients with hypophosphatemic rickets/osteomalacia, fibroblast growth factor 23(FGF23)has emerged as a humoral factor that reduces serum phosphate. Discovery of FGF23 as an essential regulator of phosphate homeostasis has markedly improved our understanding of phosphate homeostasis and hypophosphatemic or hyperphosphatemic disorders. A nationwide epidemiologic survey of FGF23-related hypophosphatemic diseases indicated that the patients showed FGF23 levels of above 30 pg/mL by intact assay in the presence of hypophosphatemia. The survey also showed that prevalence and biochemical data before and after treatment of the diseases. Novel therapeutic methods for these disorders may be developed by elucidation of the mechanism of action of FGF23.
Asunto(s)
Factores de Crecimiento de Fibroblastos/fisiología , Hipofosfatemia/epidemiología , Animales , Biomarcadores/sangre , Proteínas de la Matriz Extracelular/genética , Factor-23 de Crecimiento de Fibroblastos , Factores de Crecimiento de Fibroblastos/sangre , Factores de Crecimiento de Fibroblastos/genética , Homeostasis , Humanos , Hipofosfatemia/diagnóstico , Hipofosfatemia/etiología , Hipofosfatemia/metabolismo , Ratones , Mutación , Endopeptidasa Neutra Reguladora de Fosfato PHEX/genética , Fosfatos/metabolismo , Fosfoproteínas/genética , Hidrolasas Diéster Fosfóricas/genética , Prevalencia , Pirofosfatasas/genética , Raquitismo Hipofosfatémico/etiologíaRESUMEN
Fibroblast growth factor 23 (FGF23) is an essential hormone for phosphate metabolism. It has been shown that intravenous administration of some iron formulations including saccharated ferric oxide induces hypophosphatemic osteomalacia with high FGF23 levels. On the other hand, iron deficiency promotes FGF23 and induces hypophosphatemia in patients with autosomal dominant hypophosphatemic rickets (ADHR). While iron and phosphate metabolism is connected, the detailed mechanism of this connection remains to be clarified.
Asunto(s)
Hierro/metabolismo , Fosfatos/metabolismo , Anemia Ferropénica/complicaciones , Anemia Ferropénica/metabolismo , Compuestos Férricos/administración & dosificación , Compuestos Férricos/efectos adversos , Sacarato de Óxido Férrico , Factor-23 de Crecimiento de Fibroblastos , Factores de Crecimiento de Fibroblastos/metabolismo , Factores de Crecimiento de Fibroblastos/fisiología , Ácido Glucárico/administración & dosificación , Ácido Glucárico/efectos adversos , Humanos , Hipofosfatemia/inducido químicamente , Hipofosfatemia/metabolismo , Inyecciones Intravenosas , Osteomalacia/inducido químicamente , Osteomalacia/metabolismo , Insuficiencia Renal Crónica/metabolismo , Raquitismo Hipofosfatémico/etiología , Raquitismo Hipofosfatémico/metabolismoRESUMEN
BACKGROUND: Tumor-associated fibroblast growth factor 23 (FGF-23)-induced hypophosphatemic rickets is a rare but known pediatric entity first described in 1959. It results from local production of phosphatonins by benign and malignant mesenchymal tumors. CASE-DIAGNOSIS/TREATMENT: We report an 8-year-old boy with tumor-associated hypophosphatemic rickets due to paraneoplastic FGF-23 secretion from a benign mesenchymal pelvic-bone tumor. Excessive FGF-23 production was visualized by immunohistochemistry in the resected tumor. Phosphate wasting stopped immediately after tumor resection. We reviewed 26 reports of pediatric patients with tumor-induced hypophosphatemic rickets; paraneoplastic FGF-23 secretion was documented in only three of them. All tumors developed inside bone, were benign in 21/26 cases, and were localized in femur/tibia (13/26), radius/ulna/humerus (7/26), pelvis (4/26), rib (1/26), and craniofacial (1/26) bones. Mean interval between onset of signs and/or symptoms and diagnosis was 34 months. CONCLUSIONS: In patients with hypophosphatemic rickets acquired beyond infancy, radiologic investigations for bone tumors need to be performed rapidly. In contrast to biochemical screening for increased circulating FGF-23 levels, immunohistochemical confirmation of FGF-23 production in resected tumor tissue can be regarded as being well established.
Asunto(s)
Neoplasias Óseas/complicaciones , Factores de Crecimiento de Fibroblastos/biosíntesis , Raquitismo Hipofosfatémico/etiología , Neoplasias Óseas/metabolismo , Niño , Factor-23 de Crecimiento de Fibroblastos , Humanos , Inmunohistoquímica , MasculinoAsunto(s)
Neoplasias de Tejido Conjuntivo/diagnóstico por imagen , Neoplasias de Tejido Conjuntivo/cirugía , Raquitismo Hipofosfatémico/diagnóstico por imagen , Raquitismo Hipofosfatémico/cirugía , Femenino , Humanos , Persona de Mediana Edad , Neoplasias de Tejido Conjuntivo/complicaciones , Osteomalacia , Síndromes Paraneoplásicos , Cintigrafía , Raquitismo Hipofosfatémico/etiologíaRESUMEN
The common denominator for all types of rickets is hypophosphatemia, leading to inadequate supply of the mineral to the growing bone. Hypophosphatemia can result from insufficient uptake of the mineral from the gut or its disproportionate losses in the kidney, the latter being caused by either tubular abnormalities per se or the effect on the tubule of circulating factors like fibroblast growth factor-23 and parathyroid hormone (PTH). High serum levels of the latter result in most cases from abnormalities in vitamin D metabolism which lead to decreased calcium absorption in the gut and hypocalcemia, triggering PTH secretion. Rickets is a disorder of the growth plate and hence pediatric by definition. However, it is important to recognize that the effect of hypophosphatemia on other parts of the skeleton results in osteomalacia in both children and adults. This review addresses the etiology, pathophysiologic mechanisms, clinical manifestations and treatment of entities associated with hypophosphatemic rickets due to perturbations in renal tubular function.
Asunto(s)
Placa de Crecimiento/metabolismo , Túbulos Renales Proximales/metabolismo , Osteogénesis , Fosfatos/metabolismo , Raquitismo Hipofosfatémico/etiología , Factores de Edad , Predisposición Genética a la Enfermedad , Placa de Crecimiento/fisiopatología , Humanos , Túbulos Renales Proximales/fisiopatología , Pronóstico , Raquitismo Hipofosfatémico/diagnóstico , Raquitismo Hipofosfatémico/genética , Raquitismo Hipofosfatémico/metabolismo , Raquitismo Hipofosfatémico/fisiopatología , Raquitismo Hipofosfatémico/terapia , Factores de RiesgoRESUMEN
Some of the hypophosphatemic rickets/osteomalacia are caused by the increased bioactivity of FGF23, and classified into FGF23-mediated hypophosphatemic rickets/osteomalacia. This group includes various disorders such as X-linked, autosomal dominant and autosomal recessive hypophosphatemic rickets/osteomalacia, tumor-induced osteomalacia, and rickets/osteomalacia caused by the administration of iron polymaltose or saccharated ferric oxide. Measurement of serum levels of FGF23 is useful for diagnosis of these conditions. In the adult patients with FGF23-mediated hypophosphatemic rickets/osteomalacia, mineralizing enthesoopathy is an often observed complication.
Asunto(s)
Factores de Crecimiento de Fibroblastos/sangre , Osteomalacia/diagnóstico , Raquitismo Hipofosfatémico/diagnóstico , Diagnóstico Diferencial , Compuestos Férricos/efectos adversos , Sacarato de Óxido Férrico , Factor-23 de Crecimiento de Fibroblastos , Ácido Glucárico/efectos adversos , Humanos , Osteomalacia/sangre , Osteomalacia/etiología , Fosfatos/sangre , Raquitismo Hipofosfatémico/sangre , Raquitismo Hipofosfatémico/etiologíaAsunto(s)
Neoplasias Óseas/complicaciones , Neoplasias Óseas/diagnóstico , Imagen Multimodal , Neoplasias de Tejido Conjuntivo/complicaciones , Neoplasias de Tejido Conjuntivo/diagnóstico , Raquitismo Hipofosfatémico/diagnóstico , Raquitismo Hipofosfatémico/etiología , Artralgia/diagnóstico , Artralgia/etiología , Niño , Diagnóstico Diferencial , Humanos , Articulación de la Rodilla , Masculino , Osteomalacia , Síndromes Paraneoplásicos , Radiografía , Cintigrafía , Tibia/diagnóstico por imagen , Tibia/patologíaRESUMEN
OBJECTIVE: To present clinical and etiological profile of refractory rickets from Mumbai. METHODS: Case records of 36 patients presenting over 2½ y with refractory rickets were evaluated with respect to clinical presentation, biochemical, radiological features and where needed, ophthalmological examination, ultrasonography and special tests on blood and urine. RESULTS: Twenty three (63 %) patients had renal tubular acidosis (RTA)-distal RTA in 20 and proximal RTA in 3 patients; 5 (14 %) had vitamin D dependent rickets (VDDR I in 2 and VDDR II in 3 patients), 4 (11 %) had chronic renal failure (CRF) and 2 each (6 %) had hypophosphatemic rickets and chronic liver disease as cause of refractory rickets. A significant proportion of patients with RTA and VDDR showed skeletal changes of rickets in the first 2 y of life, while those with hypophosphatemic rickets presented later. Patients with hypophosphatemic rickets had predominant involvement of lower limbs, normal blood calcium and PTH levels and phosphorus leak in urine. All patients with RTA presented with failure to thrive, polyuria and marked rickets; blood alkaline phosphatase levels being normal in almost 50 % patients. Three (75 %) patients with rickets due to CRF had GFR < 30 ml/min/1.73 m(2) and hyperphosphatemia. Patients with cirrhosis due to biliary atresia had rickets inspite of taking high dose of vitamin D orally. CONCLUSIONS: Refractory rickets is a disorder of multiple etiologies; a good history and clinical examination supplemented with appropriate investigations helps to determine its cause.